Viral hepatitis remains one of the most significant yet under-discussed public health challenges in Asia. China's experience with hepatitis B and C provides a sobering case study that holds valuable lessons for India as it works to strengthen its own disease surveillance and prevention systems.
Understanding the Hepatitis Burden
Hepatitis refers to inflammation of the liver, commonly caused by viral infections. The most concerning forms are hepatitis B and C, which can lead to chronic liver disease, cirrhosis, and liver cancer. China has historically carried one of the world's highest burdens of hepatitis B, with approximately 90 million people living with chronic infection at its peak.
India faces a similar challenge, though exact numbers remain unclear due to inadequate surveillance. Estimates suggest that 40 million Indians may be living with chronic hepatitis B, and another 6-12 million with hepatitis C. The lack of precise data itself represents a critical weakness in India's public health infrastructure.
China's Vaccination Success Story
One area where China has demonstrated remarkable progress is in hepatitis B vaccination. Starting in the 1990s, China implemented a comprehensive vaccination program targeting newborns. By making the hepatitis B vaccine part of the national immunization schedule and ensuring coverage even in rural areas, China reduced the prevalence among children under five from nearly 10 percent to less than 1 percent.
This achievement came through sustained government commitment, adequate funding, and systematic implementation. Free vaccines were provided, healthcare workers were trained extensively, and public awareness campaigns reached even remote populations.
India's Vaccination Gaps
India introduced hepatitis B vaccination into its Universal Immunization Programme in 2002-2003, but coverage remains inconsistent. While urban areas generally achieve good vaccination rates, rural and underserved communities often lag behind. The birth dose, which is critical for preventing mother-to-child transmission, is not universally administered within the recommended 24-hour window.
India can learn from China's emphasis on the birth dose and its strategies for reaching the last mile. This requires strengthening cold chain infrastructure, ensuring vaccine availability at all health facilities including those conducting home deliveries, and training frontline health workers.
The Screening and Treatment Challenge
China's experience also highlights the importance of screening and treatment. For years, China had millions of people living with chronic hepatitis unaware of their status. The country has recently invested heavily in screening programs and making treatment more accessible and affordable.
India faces similar challenges. Most people with chronic hepatitis B or C in India are undiagnosed. Without knowing their status, they cannot access treatment, and they unknowingly risk transmitting the virus to others. Furthermore, antiviral treatments, while available, remain expensive and inaccessible for many.
Stigma and Discrimination
Both China and India struggle with stigma surrounding hepatitis. In China, people with hepatitis B have faced employment discrimination, social ostracization, and barriers to education. Legal protections exist but enforcement remains weak.
India must proactively address stigma through public education campaigns that clarify how hepatitis is and is not transmitted. Many people wrongly believe hepatitis B spreads through casual contact, leading to unnecessary social exclusion.
Surveillance Systems Need Strengthening
Perhaps the most critical lesson from China is the importance of robust disease surveillance. China invested in systems to track hepatitis prevalence, monitor treatment outcomes, and identify high-risk populations. While imperfect, these systems provided data to guide policy decisions.
India's surveillance for hepatitis remains fragmented. National-level data is sparse, and many states lack comprehensive monitoring systems. Without reliable data, it becomes difficult to allocate resources effectively or measure program success.
Integration with Existing Programs
India has an opportunity to integrate hepatitis prevention and care into existing health initiatives. The Ayushman Bharat program and Health and Wellness Centers could incorporate hepatitis screening. Maternal and child health programs could strengthen birth dose vaccination. HIV programs could include hepatitis co-infection screening, as many people are at risk for both.
The Path Forward
Addressing India's hepatitis burden requires political will, sustained funding, and coordinated action across multiple levels of government. Key priorities should include achieving universal birth dose vaccination, expanding screening programs, improving data collection, reducing treatment costs, and combating stigma.
China's experience demonstrates that progress is possible even in large, diverse countries with resource constraints. However, it also shows that progress requires decades of sustained effort. India must act now to prevent millions of future cases of chronic liver disease and liver cancer.
This article is for general informational purposes only and should not be considered medical advice. Individuals concerned about hepatitis should consult qualified healthcare professionals for screening, diagnosis, and treatment recommendations.
